The January 2017 issue of Clinical Chemistry includes a mini review of biomarkers for clinical decision making in the management of pulmonary embolism.
In this podcast, we're joined by one of the authors, Dr. Evangelos Giannitsis. He is an Assistant Professor of Medicine at the Department of Cardiology at the University of Heidelberg, Germany. Dr. Giannitsis served on the program committee of the European Society of Cardiology and is a member of the organization's working group for cardiac biomarkers. So Dr. Giannitsis, what is the most important difference between the previous and the current ESG On the other hand, the patient with a low risk, he is somebody who could be considered for early discharge home and home treatment. So this is totally a new concept of risk stratification and patient management.
Bob Barrett: How did the PEITHO study influence risk stratification concepts?
Dr. Giannitis: The PEITHO study was randomized trial on 1,005 patients with hemodynamically stable pulmonary embolism, especially the group of interest in whom risk stratification could show beneficial effects of thrombolytic therapy. So in this group, patients were randomized to receive thrombolytic therapy if they fulfilled the criteria of having right ventricular dysfunction by imaging, or an elevated biomarker of myocardial injury and in that study, troponin was selected as the marker of choice for this.
Unfortunately, the results of the PEITHO trial were not as expected. So on the one hand, there was a benefit of thrombolytic therapy among patients who had elevated biomarkers plus the right ventricular dysfunction, but these patients also suffered significantly more major bleedings. So the concept of directing a patient with high-risk features to thrombolytic therapy was not confirmed by this trial, and the whole concept of risk stratification and allocation to therapy was reconsidered. And after that, several new risk stratification scores were developed and validated in order to have more precise individualized risk stratification and management options for patients with hemodynamically stable pulmonary embolism.
Bob Barrett:
What role do biomarkers play in the management of pulmonary embolism?
Dr. Giannitis: Biomarkers are very important tools. They give us information on myocardial injury or pressure and stress overload to the heart, particularly to the right ventricle.
And they were used to risk estimate the patient into intermediate risk patient requiring thrombolytic therapy, or not. Nowadays, the biomarker information is important in order to give adjunctive information to clinical scores, and if a patient has an intermediate risk and has both evidence of right ventricular dysfunction by imaging and a positive biomarker result, then he is classified as an intermediate high risk patient, and again, these patients need monitoring to detect the compensation earlier or to detect the need of rescue reperfusion therapy. 
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